Myeloma cell therapies, now in pharma hands, move into spotlight

Myeloma cell therapies, now in pharma hands, move into spotlight

A Cure for Cancer? How CAR T-Cell Therapy is Revolutionizing Oncology

A Cure for Cancer? How CAR T-Cell Therapy is Revolutionizing Oncology

Ο πρώτος… Άγγλος ασθενής λαμβάνει πανάκριβη θεραπεία

Ο πρώτος… Άγγλος ασθενής λαμβάνει πανάκριβη θεραπεία

Doubling Down on Gene Therapies, Novartis Buys CellforCure to Manufacture CAR-T Products

Doubling Down on Gene Therapies, Novartis Buys CellforCure to Manufacture CAR-T Products

Miracle Drugs Don’t Always Work— A Rare but Lethal Case of an Immuno-Oncology Backfire

Miracle Drugs Don’t Always Work— A Rare but Lethal Case of an Immuno-Oncology Backfire

Pharm Exec’s 2019 Pipeline Report

Pharm Exec's 2019 Pipeline Report

Ash 2018 preview – blood cancers offer biotech a chance at redemption

The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.   Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!! For biotech the past month or so has been ugly. The Esmo meeting … Συνεχίστε να διαβάζετε Ash 2018 preview – blood cancers offer biotech a chance at redemption.